RT Journal Article
SR Electronic
T1 Monitoring the evolution of the COVID-19 pandemic in China, South Korea, Italy and USA through the net relative rate of infection of the total number of confirmed cases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.15.20103259
DO 10.1101/2020.05.15.20103259
A1 Moreira, João Manoel Losada
YR 2020
UL http://medrxiv.org/content/early/2020/05/20/2020.05.15.20103259.abstract
AB Managing the COVID-19 pandemic in the middle of the events requires real-time monitoring of its evolution to perform analyses of containment actions and to project near future scenarios. This work proposes a scheme to monitor the temporal evolution of the COVID-19 pandemic using the time series of its total number of confirmed cases in a given region. The monitored parameter is the spread rate obtained from this time series (day−1) expressed in %/day. The scheme’s capability is verified using the epidemic data from China and South Korea. Its projection capability is shown for Italy and United States with scenarios for the ensuing 30 days from April 2nd, 2020. The spread rate (relative rate of change of the time series) is very sensitive to sudden changes in the epidemic evolution and can be used to monitor in real-time the effectiveness of containment actions. The logarithm of this variable allows identifying clear trends of the evolution of the COVID-10 epidemic in these countries. The spread rate calculated from the number of confirmed cases of infection is interpreted as a probability per unit of time of virus infection and containment actions. Its product with the number of confirmed cases of infections yields the number of new cases per day. The stabilization and control of the epidemic for China and South Korea appear to occur for values of this parameter below 0·77 %/day (doubling time of 90 days).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author thanks the Brazilian agency Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for financial support and acknowledges it had no interference on data collection, interpretation, or decision to submit the work for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are referred to in the manuscript. The data were collected from: https://www.worldometers.info/coronavirus/#countries